TITLE

Categorizing Asthma Severity:An Overview of National Guidelines

AUTHOR(S)
Colice, Gene L.
PUB. DATE
August 2004
SOURCE
Clinical Medicine & Research;Aug2004, Vol. 2 Issue 3, p155
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Asthma is an inflammatory disease of the airways associated with intermittent episodes of bronchospasm. Corticosteroids are the most effective anti-inflammatory class of medication currently available for the treatment of asthma. However, as higher doses of inhaled corticosteroids are used the risks of systemic exposure and side effects will correspondingly increase. Justification of the benefits from higher doses of inhaled corticosteroids can only be made if patients with more severe asthma can be identified. Methods to categorize asthma severity have been introduced in various national asthma management guidelines. Unfortunately, there are substantial conceptual and practical differences among these recommended approaches to asthma severity categorization. Furthermore, these recommended approaches suffer from a focus on features of asthma control, such as symptoms, short-acting beta-agonist use, and lung function rather than actual measures of asthma severity that would encompass markers of airway inflammation. Without the endpoints necessary to assess airway inflammation, current recommendations for asthma severity categorization may lead to systematic under dosing of appropriate anti-inflammatory therapy with subsequent perpetuation of the asthma exacerbation cycle.
ACCESSION #
14527334

 

Related Articles

  • Leukotriene Generation and Clinical Implications. Arm, Jonathan P. // Allergy & Asthma Proceedings;Jan/Feb2004, Vol. 25 Issue 1, p37 

    Since the elucidation of the structure of the cysteinyl leukotrienes (LTs) >20 years ago, considerable progress has been made in our understanding of the role of these molecules in health and disease, particularly regarding bronchial asthma. This study will review the biochemistry of the...

  • Asthma Improved by Nonsteroidal Anti-Inflammatory Drugs. Kordansky, Daniel; Adkinson, N. Franklin; Norman, Philip S.; Rosenthal, Richard R. // Annals of Internal Medicine;Apr78, Vol. 88 Issue 4, p508 

    Provides information on a study that investigated the role of aspirin and other non steroidal anti-inflammatory drug in improving asthma and inhibiting the prostaglandin synthetase enzyme system. Materials and methods used; Results and discussion.

  • Nedocromil: A new agent for the treatment of asthma. Keenan, Jeph M. // American Family Physician;10/1/1994, Vol. 50 Issue 5, p1059 

    Investigates the use of nedocromil sodium as an anti-inflammatory agent for the treatment of mild to moderate asthma. Pharmacodynamics; Pharmacokinetics; Toxicity; Side effects; Clinical experience; Clinical indications and dosage; Management issues.

  • Blocking leukotrienes optimize asthma control: The BLOC survey. Idrees, Majdy M.; Al Moamary, Mohamed S. // Annals of Thoracic Medicine;Jul-Sep2007, Vol. 2 Issue 3, p99 

    Objective: The aim of this study was to evaluate asthma control after the introduction of a leukotriene modifier (Montelukast), in addition to the current controller asthma therapies, in patients with inadequately controlled mild-to-moderate persistent asthma. Asthma control and patient...

  • Combination therapies for asthma. Greener, Mark // British Journal of Healthcare Management;2015, Vol. 21 Issue 1, p12 

    Combination inhalers are one of the five most expensive drug groups in the UK. Expenditure may rise further following the launch of several new combinations for asthma, chronic obstructive pulmonary disease (COPD), or both. Despite clear advice, healthcare professionals (HCPs) often prescribe...

  • Management Options in Childhood Asthma -- What is the Current Evidence on which Treatment is Based? Lenney, Warren // Current Pediatric Reviews;2010, Vol. 6 Issue 2, p121 

    In contrast to the adult population, many medicines used in children with asthma have been inadequately studied with the result that evidence for their usage is lacking. Short-acting bronchodilators and inhaled corticosteroids have been available for over 40 years and thankfully, evidence for...

  • IDADE COMO VARIÁVEL NA RESPOSTA BRONCOMOTORA ADRENÉRGICA/ COLINÉRGICA. LOUREIRO, Cláudia Chaves // Acta Medica Portuguesa;2011, Vol. 24 Issue 2, p231 

    Background: Changes of pulmonary mechanisms, receptor population and nervous control of the airway, that occur with ageing, are responsible for the different clinical presentation of pathologies like asthma, as well as different efficacy of bronchodilator therapeutics in the aged patient. To be...

  • Anti-asthmatic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p66 

    The article presents information on anti-asthmatic agents. Anti-asthma drugs relieve the symptoms of bronchial asthma or prevent recurrent attacks. Two main types of drugs are used: one group treat acute attacks; and the second prevent attacks. Bronchodilators work by dilating and relaxing the...

  • Bronchodilators for Bronchiolitis. FOGLEMAN, COREY D. // American Family Physician;11/1/2014, Vol. 90 Issue 9, p622 

    The article discusses research on whether inhaled bronchodilator such as albuterol should be used to treat a child aged 2 years old or younger with bronchiolitis. It references the study "Bronchodilators for Bronchiolitis," by A. M. Gadomski et al. published in a 2014 issue of the journal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics